DLA Piper scoops $6.7bn biotech merger

June 19, 2008 DLA Piper has scored a role in one of the biggest pharmaceutical deals of the year, lining up alongside Skadden Arps Slate Meagher & Flom in the $6.7bn (£3.4bn) merger of US biotechnology suppliers Invitrogen and the Applera Corporation.

Read more at www.thelawyer.com.

comments powered by Disqus